non fda approved glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 The expanding scope of GLP-1

Short-chain fatty acids, particularly butyrate and propionate, have been shown to activate receptors on enteroendocrine L-cells, triggering GLP-1 release

But healthy weight loss isnt just about the number on the scale its about losing fat while protecting your muscles and keeping your natural, healthy shape

Pharmacy benefit managers (PBMs) contracted with Cigna occasionally impose quantity limits or refill restrictions, capping monthly injections even if your physician determines higher doses are medically necessary

Patients with high A1c often achieve only about half the weight loss predicted for non-diabetics

Patients report fewer gastrointestinal issues at reduced levels, improving adherence

GLP-1 drugs produce dramatic, rapid weight loss by maintaining supraphysiological levels of synthetic GLP-1 in the bloodstream around the clock